FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046451711> ?p ?o ?g. }

• W3046451711 endingPage "e21447" @default.
• W3046451711 startingPage "e21447" @default.
• W3046451711 abstract "Background: The comparative efficacy and safety of small molecule and biological agents in the treatment of psoriatic arthritis (PsA) remain unknown. Objectives: To compare the efficacy and safety of 14 small molecule and biological agents by network meta-analysis (NMA). Methods: Relevant randomized controlled trials involving biological treatments for PsA were identified by searching PubMed, Cochrane Library, EMBASE, Web of Science, and Clinicaltrials.gov and by manual retrieval, up to June 2018. NMA was conducted with Stata 14.0 based on the frequentist method. Effect measures were odds ratios (ORs) with 95% confidence intervals (CIs). Intervention efficacy and safety were ranked according to the surface under the cumulative ranking curve (SUCRA). Results: A total of 30 studies involving 10,191 adult subjects were included. According to NMA, ≥ 20% improvement in modifed American College of Rheumatology response criteria (ACR20) response, Psoriasis Area and Severity Index 75 (PASI75) response, and serious adverse events rate (SAEs) were observed. In direct comparisons, most of the biologics performed better than placebo in terms of ACR20 response rate and PASI75 response rate. Additionally, all medicines were comparable to placebo in terms of SAEs except secukinumab. In terms of mixed comparisons, with regard to the ACR20 response, etanercept (ETN) and infliximab (IFX) were more effective than golimumab (GOL), with ORs of 3.33 (95% CI: 1.17–9.48) and 1.24 (95% CI: 0.61–2.52), respectively. For PASI75 response, IFX was superior to certolizumab pegol (OR = 10.08, 95% CI: 1.54–75.48). In addition, these medicines were comparable to each other in terms of SAEs. ETN and IFX were shown to have the most favorable SUCRA for achieving improved ACR20 and PASI75 responses, respectively, while ABT-122 exhibited the best safety according to the SUCRA for SAEs. Considering both the efficacy (ACR20, PASI75) and safety (SAEs), GOL, ETN, and IFX are the top 3 treatments. Conclusions and Implications: Direct and indirect comparisons and integrated results suggested that the 3 anti- tumor necrosis factor -α biologics (GOL, ETN, and IFX) can be considered the best treatments for PsA after comprehensive consideration of efficacy and safety." @default.
• W3046451711 created "2020-08-07" @default.
• W3046451711 creator A5015420146 @default.
• W3046451711 creator A5027286192 @default.
• W3046451711 creator A5029639031 @default.
• W3046451711 creator A5033704686 @default.
• W3046451711 creator A5039433604 @default.
• W3046451711 creator A5064926505 @default.
• W3046451711 creator A5065715690 @default.
• W3046451711 creator A5091631406 @default.
• W3046451711 date "2020-07-31" @default.
• W3046451711 modified "2023-10-16" @default.
• W3046451711 title "Fourteen small molecule and biological agents for psoriatic arthritis" @default.
• W3046451711 cites W1922566561 @default.
• W3046451711 cites W1935617463 @default.
• W3046451711 cites W1973040111 @default.
• W3046451711 cites W1981700374 @default.
• W3046451711 cites W2008873550 @default.
• W3046451711 cites W2009923660 @default.
• W3046451711 cites W2013143792 @default.
• W3046451711 cites W2024494874 @default.
• W3046451711 cites W2045317929 @default.
• W3046451711 cites W2048626246 @default.
• W3046451711 cites W2053127888 @default.
• W3046451711 cites W2061205096 @default.
• W3046451711 cites W2083180635 @default.
• W3046451711 cites W2094124191 @default.
• W3046451711 cites W2097973532 @default.
• W3046451711 cites W2098923148 @default.
• W3046451711 cites W2108984264 @default.
• W3046451711 cites W2133696182 @default.
• W3046451711 cites W2137101132 @default.
• W3046451711 cites W2145778588 @default.
• W3046451711 cites W2149168537 @default.
• W3046451711 cites W2149793775 @default.
• W3046451711 cites W2151280501 @default.
• W3046451711 cites W2166077573 @default.
• W3046451711 cites W2167795826 @default.
• W3046451711 cites W2168505126 @default.
• W3046451711 cites W2168698481 @default.
• W3046451711 cites W2192463491 @default.
• W3046451711 cites W2194197257 @default.
• W3046451711 cites W2195835569 @default.
• W3046451711 cites W2223868808 @default.
• W3046451711 cites W2266045195 @default.
• W3046451711 cites W2297053275 @default.
• W3046451711 cites W2314434775 @default.
• W3046451711 cites W2339525054 @default.
• W3046451711 cites W2342299171 @default.
• W3046451711 cites W2471133371 @default.
• W3046451711 cites W2512436288 @default.
• W3046451711 cites W2588681363 @default.
• W3046451711 cites W2592793178 @default.
• W3046451711 cites W2611521096 @default.
• W3046451711 cites W2620369605 @default.
• W3046451711 cites W2736598400 @default.
• W3046451711 cites W2744362817 @default.
• W3046451711 cites W2766717228 @default.
• W3046451711 cites W2782272615 @default.
• W3046451711 cites W2783179629 @default.
• W3046451711 cites W2789710874 @default.
• W3046451711 cites W2795686103 @default.
• W3046451711 cites W2797662273 @default.
• W3046451711 cites W2806161046 @default.
• W3046451711 cites W4241915332 @default.
• W3046451711 doi "https://doi.org/10.1097/md.0000000000021447" @default.
• W3046451711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7402795" @default.
• W3046451711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32756163" @default.
• W3046451711 hasPublicationYear "2020" @default.
• W3046451711 type Work @default.
• W3046451711 sameAs 3046451711 @default.
• W3046451711 citedByCount "2" @default.
• W3046451711 countsByYear W30464517112022 @default.
• W3046451711 crossrefType "journal-article" @default.
• W3046451711 hasAuthorship W3046451711A5015420146 @default.
• W3046451711 hasAuthorship W3046451711A5027286192 @default.
• W3046451711 hasAuthorship W3046451711A5029639031 @default.
• W3046451711 hasAuthorship W3046451711A5033704686 @default.
• W3046451711 hasAuthorship W3046451711A5039433604 @default.
• W3046451711 hasAuthorship W3046451711A5064926505 @default.
• W3046451711 hasAuthorship W3046451711A5065715690 @default.
• W3046451711 hasAuthorship W3046451711A5091631406 @default.
• W3046451711 hasBestOaLocation W30464517111 @default.
• W3046451711 hasConcept C126322002 @default.
• W3046451711 hasConcept C142724271 @default.
• W3046451711 hasConcept C156957248 @default.
• W3046451711 hasConcept C1862650 @default.
• W3046451711 hasConcept C197934379 @default.
• W3046451711 hasConcept C204787440 @default.
• W3046451711 hasConcept C27081682 @default.
• W3046451711 hasConcept C2776215756 @default.
• W3046451711 hasConcept C2776260265 @default.
• W3046451711 hasConcept C2777077863 @default.
• W3046451711 hasConcept C2777138892 @default.
• W3046451711 hasConcept C2777226972 @default.
• W3046451711 hasConcept C2777575956 @default.
• W3046451711 hasConcept C2779134260 @default.
• W3046451711 hasConcept C2779786854 @default.

• next